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Introduction
The collection of comparative effectiveness data and Health
Technology Assessment (HTA) has been practiced for decades,
particularly in Europe. Indeed, efforts to use some kind of evi-
dence to guide health-care practices in Sweden were ﬁrst docu-
mented 350 years ago upon the establishment of the Medical
Collegium in 1663, whose tasks were to distinguish quackery
from medicine, to develop a pharmacopeia, and to control the
trade of poisonous drugs. The Collegium required yearly reports
from district physicians in which they were urged to describe the
disease proﬁles of local areas that included information on the
available drugs and their use, the level of medical treatment, and
crude treatment outcomes such as improved or deceased, as well
as information about the lifestyles of the population, nutrition,
housing conditions, levels of alcoholism, and literacy. Subse-
quently, assessment of health practices have steadily evolved in
Sweden’s health-care agencies and institutions. Today, Sweden
has a wide ranging assessment system, in which the concept of
comparative effectiveness is included in a national HTA and drug
approval process, although there are not many “true compara-
tive effectiveness” results (e.g., head to head trials) available in
the literature so far.
HTA
HTA was created in the 1970s when the computerized tomogra-
phy (CT) scanner was introduced. Policymakers felt they needed
more evidence than promises of the new technology and called
upon the scientiﬁc community to provide synthesized informa-
tion about its clinical, economic, social, ethical, and budget
impact implications. That multidisciplinary and policy oriented
approach was then called medical technology assessment, later
named HTA.
Not surprisingly, HTA today is much different from then,
covering the whole health-care spectrum. As such, HTA includes
drugs, devices and equipment, and the medical, surgical, and
other procedures used in prevention, diagnosis treatment and
rehabilitation of disease and disability. The methodologies have
improved tremendously over the years, and nowadays, there are
more than 50 HTA agencies around the world and thousands of
academics employed in the HTA ﬁeld. Indeed, the growth of this
ﬁeld saw an international HTA society, The International Society
for Health Technology Assessment established in 1985, as well as
the publication of the ﬁrst issue of the International Journal of
Technology Assessment in Healthcare (IJTAHC). Today, the
society has reformed under Health Technology Assessment Inter-
national and has about 1000 members. The Journal has a quar-
terly distribution of 4000. Over the years, IJTAHC has published
about 2000 manuscripts authored by about 5000 scholars,
describing assessments of different health practices and technolo-
gies. Despite the growth of expertise in the ﬁeld and indications
that HTA could substantially beneﬁt from attention being paid to
the issue of comparing the effectiveness of different technologies,
many agencies, institutions, departments, and pharmaceutical
companies continue to focus their search for evidence of the
effectiveness of one drug, one device, or one other piece of
technology, in isolation.
HTA in Sweden
In the early 1980s, the government of Sweden initiated discus-
sions around the need to establish an agency to review all health-
care practices and technologies in use in the country. Within a
few years, an HTA agency known as the Swedish Council on
Technology Assessment in Healthcare (SBU) was established. Of
note, and perhaps integral to its success, multiple stakeholders
were involved in the formation of SBU, including researchers in
clinical medicine and health services research, particularly health
economists, policymakers and individuals with political inﬂu-
ence. Indeed, the Minister of Finance personally attended many
of the discussions and, as in the UK, the focus was not to save
money, but to make more effective use of existing resources and
improve the quality of care by giving people access to new,
effective technology as soon as possible. Another important
objective for Sweden was to obtain reliable information in order
to set health-care priorities.
Processes
Although the concept of comparative effectiveness had not yet
been coined, it was clearly stated by the Minister of Health that
the newly formed SBU should give priority to assessing major
disease areas and simultaneously evaluate and compare the effec-
tiveness of all technologies used for prevention, diagnosis, and
treatment. The ﬁrst disease area to be considered by SBU was
diagnosing and treatment of unspeciﬁc neck and low back pain,
followed by hypertension, obesity, depression, and dementia.
As with most HTA organizations, the SBU assessment process
includes a systematic review of the scientiﬁc literature that iden-
tiﬁes all available technologies; a context-speciﬁc cost-
effectiveness analysis; a review of the ethical and social issues;
and development of policy options and implications. The reviews
are conducted by a team of 10 to15 individuals, generally having
research backgrounds. Each review is quite time consuming as it
may require consideration of as many as 50 technologies. For
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example, the SBU identiﬁed more than 20,000 studies in its
assessment of unspeciﬁc neck and low back pain. More than 600
of these, describing 40 different technologies used in prevention,
diagnosis, and treatment were used to form conclusions about
the relative, or comparative effectiveness in this area. Of note, the
deliberate involvement of those affected by the ﬁndings has
ensured a strong connection between SBU and clinicians
throughout the country.
Assessment Results
Disease Area: Alcohol and Drug Abuse
SBU completed this review in 2004. They concluded that there
was clear evidence of effectiveness for essentially all drugs used in
the treatment of alcohol and drug abuse but found a considerable
amount of evidence that drug therapy is signiﬁcantly underused
as a technology in this disease area.
Disease Area: Unspeciﬁc Low Back Pain
Despite a large fraction of the capacity of magnetic resonance
imaging and CT scanning being taken up by patients with unspe-
ciﬁc, low back pain, upon assessing 13 different diagnostic tech-
nologies used in diagnosing this condition (Table 1), SBU found
that only one intervention, namely physical examination, is sup-
ported by strong evidence that it is a useful diagnostic measure.
Similarly, despite a long list of potential treatments, many have
been proven ineffective (Table 2).
Disease Area: Obesity
Importantly, in addition to identifying the evidence for or against
diagnostics and treatments, SBU assessments draw attention to
the relative beneﬁts of speciﬁc interventions. For example, the use
of pharmacotherapy for obesity may signiﬁcantly reduce weight,
but only by a relatively small amount per year. This has led to a
tendency for many people to disregard it as a useful intervention.
Although surgery was shown being the option with best evidence
of sustainable weight loss and positive impact on ﬁnal end out-
comes, the review demonstrates that pharmaceuticals do much
better than many other interventions (Table 3).
Concluding Remarks
After more than 20 years of intensive work on evidence based
medicine, and HTA at both the national (SBU) and the local level
(the 25 regions/county councils), along with substantially
strengthened mechanisms for assessment of pharmaceuticals
through the TLV (the Dental and Pharmaceutical Beneﬁts Board,
which not only makes national pricing and reimbursement deci-
sions, but also extensive assessments in the ﬁeld of health tech-
nologies, Sweden now has quite some experience in approaching
the coming era of comparative effectiveness (as launched in
the US) and relative effectiveness (as launched by the European
Commission).
Source of ﬁnancial support: Oxford Outcomes, the National Pharmaceu-
tical Council, and Shire Pharmaceuticals.
Table 1 Technologies used to diagnose unspeciﬁc low back pain
Physical examination Facet blocks
Mobility and muscle tests Stress radiography
X-ray Discography
Magnetic resonance imaging Nerve root inﬁltration
Computed tomography scanning Bone scintigraphy
Neurophysiologic tests including electromyography
(EMG)
Thermography
Ultrasound
Table 2 Comparative effectiveness in treatment of nonspeciﬁc low back
pain
Acute Chronic
Rest or bed rest Strong evidence
against
Strong evidence against
Traction No evidence Moderate evidence against
Antidepressants No evidence Moderate evidence against
Biofeedback Unknown Moderate evidence against
Epidural steroid injection No evidence Unknown
No nerve root pain No evidence No evidence
Cold No evidence No evidence
Heat No evidence No evidence
Injection into trigger
points
No evidence No evidence
Injection into ligaments No evidence No evidence
Massage No evidence No evidence
Shortwave diathermy No evidence No evidence
Ultrasound No evidence Limited evidence
Acupuncture No evidence Limited evidence
Corsets Strong evidence for Strong evidence for
Back exercises Strong evidence for Strong evidence for
Table 3 Treatments used in obesity
Dietary counseling Behavior therapy
Very low calorie diet Physical exercise
Carbohydrate-rich diets Surgery
Protein rich diets Acupuncture
Lactovegetarian diets Aromatherapy
Dietary ﬁber supplements Caffeine
Starvation Hypnosis
Cromium Pharmacotherapy
Vinegar
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